Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Successful readministration of trastuzumab after severe immune reactions in two breast cancer patients.

Tanz R, Meillan N, Libert N, Magne N, Vedrine L, Chargari C.

Invest New Drugs. 2014 Jun;32(3):573-4. doi: 10.1007/s10637-014-0085-6. Epub 2014 Mar 29.

PMID:
24682736
2.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L.

N Engl J Med. 2001 Mar 15;344(11):783-92.

3.

Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.

Láng I, Bell R, Feng FY, Lopez RI, Jassem J, Semiglazov V, Al-Sakaff N, Heinzmann D, Chang J.

Clin Oncol (R Coll Radiol). 2014 Feb;26(2):81-9. doi: 10.1016/j.clon.2013.08.011. Epub 2013 Sep 17.

PMID:
24051172
4.

Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.

Yardley DA, Raefsky E, Castillo R, Lahiry A, Locicero R, Thompson D, Shastry M, Burris HA 3rd, Hainsworth JD.

Clin Breast Cancer. 2011 Oct;11(5):297-305. doi: 10.1016/j.clbc.2011.04.002. Epub 2011 May 5.

PMID:
21729666
5.

4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.

Janku F, Pribylova O, Zimovjanova M, Pazdrova G, Safanda M, Zemanova M, Petruzelka L.

Bull Cancer. 2004 Oct 1;91(10):E279-83. Print 2004 Oct.

6.

Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.

Ardavanis A, Tryfonopoulos D, Orfanos G, Karamouzis M, Scorilas A, Alexopoulos A, Rigatos G.

Onkologie. 2005 Nov;28(11):558-64.

PMID:
16249641
7.

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.

Gori S, Colozza M, Mosconi AM, Franceschi E, Basurto C, Cherubini R, Sidoni A, Rulli A, Bisacci C, De Angelis V, Crinò L, Tonato M.

Br J Cancer. 2004 Jan 12;90(1):36-40.

8.

Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.

Tonyali O, Benekli M, Berk V, Coskun U, Ozkan M, Yildiz R, Ucgul E, Sevinc A, Uncu D, Demirci U, Buyukberber S; Anatolian Society of Medical Oncology (ASMO).

J Cancer Res Clin Oncol. 2013 Jun;139(6):981-6. doi: 10.1007/s00432-013-1409-1. Epub 2013 Mar 5.

PMID:
23463098
9.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators.

Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11.

PMID:
23764181
10.

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.

Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP.

Cancer. 2007 Sep 1;110(5):965-72.

11.

Long-term effect of trastuzumab on QT dispersion in adjuvant treatment for patients with Her2 receptor positive breast cancer: a pilot study.

Tanriverdi O, Meydan N, Barutca S.

Med Oncol. 2012 Dec;29(5):3265-71. doi: 10.1007/s12032-012-0291-z. Epub 2012 Jun 30.

PMID:
22752572
12.

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S.

J Clin Oncol. 2011 Sep 1;29(25):3351-7. doi: 10.1200/JCO.2010.31.4930. Epub 2011 Jul 25.

PMID:
21788566
13.

Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.

Im SA, Lee KS, Ro J, Lee ES, Kwon Y, Ahn JH, Ahn JS, Kim JH, Kang HS, Shin KH, Noh DY, Park IA, Kim SB, Im YH, Ha SW.

Breast Cancer Res Treat. 2012 Apr;132(2):589-600. doi: 10.1007/s10549-011-1852-0. Epub 2011 Nov 18.

PMID:
22094934
14.

Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

Perez EA, Suman VJ, Rowland KM, Ingle JN, Salim M, Loprinzi CL, Flynn PJ, Mailliard JA, Kardinal CG, Krook JE, Thrower AR, Visscher DW, Jenkins RB.

Clin Breast Cancer. 2005 Dec;6(5):425-32.

PMID:
16381626
15.

Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.

Kelly H, Kimmick G, Dees EC, Collichio F, Gatti L, Sawyer L, Ivanova A, Dressler L, Graham ML, Carey LA.

Clin Breast Cancer. 2006 Aug;7(3):237-43.

PMID:
16942640
16.

[Combination treatment with trastuzumab and Paclitaxel as primary therapy for advanced breast cancer].

Suzuki M, Kimijima I, Ishii M.

Gan To Kagaku Ryoho. 2009 Sep;36(9):1519-23. Japanese.

PMID:
19755824
17.

Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.

Tripathy D, Seidman A, Keefe D, Hudis C, Paton V, Lieberman G.

Clin Breast Cancer. 2004 Oct;5(4):293-8.

PMID:
15507176
18.

A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.

Mirtsching B, Cosgriff T, Harker G, Keaton M, Chidiac T, Min M.

Clin Breast Cancer. 2011 Apr;11(2):121-8. doi: 10.1016/j.clbc.2011.03.007. Epub 2011 Apr 11.

PMID:
21569998
19.

Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer.

Christodoulou C, Klouvas G, Pateli A, Mellou S, Sgouros J, Skarlos DV.

Anticancer Res. 2003 Jan-Feb;23(1B):737-44.

PMID:
12680177
20.

Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J.

J Clin Oncol. 2005 Nov 1;23(31):7811-9.

PMID:
16258083

Supplemental Content

Support Center